

## **CONSTRUCTION COMMENCES AT MODERNA INNOVATION AND TECHNOLOGY CENTRE IN THE UK**

*Construction of Moderna's research, development and manufacturing facility has begun, with ground broken on the facility's site at the Harwell Science and Innovation Campus, Oxfordshire*

*Facility to provide UK public with access to domestically manufactured mRNA respiratory vaccines, pending assessment and licensure*

*UK site being built to deliver Moderna's ten-year strategic partnership with the UK government*

LONDON, UK.—(ACCESS WIRE)— 25 April, 2023—Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today commenced construction of its Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire. The MITC will encompass research, development and a manufacturing facility, which aims to provide the UK public with access to mRNA vaccines for a wide range of respiratory diseases, pending independent regulatory assessment and licensure.

**Darius Hughes, UK General Manager at Moderna, said:** “We are delighted to celebrate this important milestone today alongside our partners from the UK Government and Harwell. We look forward to continuing our collaboration throughout construction of the Moderna Innovation and Technology Centre, and beyond, to bring innovative vaccines to the UK public to help protect against emerging respiratory health threats.”

A ground breaking ceremony was attended by Dame Jenny Harries, local community leaders and representatives from the UK's health resilience and life sciences community.

The Moderna investment will create hundreds of jobs during construction and operation. The MITC will include a clinical biomarker laboratory that will be constructed by the offsite construction and engineering specialist Merit. The Drug Substance and Manufacturing facility will be fitted out by Birmingham-based engineering firm IPS and is expected to become operational in 2025.

### **Attributable quotes**

**Health Minister Maria Caulfield, said:** “Thanks to this partnership between the government and Moderna, NHS patients across the country will have access to cutting edge mRNA vaccines to fight future Covid variants and other respiratory viruses, so it's great to see construction starting on this new centre.

“Putting spades in the ground in Harwell also marks a new chapter in the country's pandemic preparedness as up to 250 million vaccines per year will be produced here – helping to keep the UK population safe in the event of a future pandemic.”

**Professor Dame Jenny Harries, chief executive of the UK Health Security Agency, said:** “This facility will significantly strengthen the UK's vaccine development and research capabilities, helping shore up our defences against future health threats, including pandemics.

“Once built, it will be capable of producing millions of vaccines against respiratory diseases and other illnesses, placing the UK at the global forefront of health science and innovation.

“Partnerships like the one we have with Moderna will help us remain agile in our response to health threats as they emerge, and the construction of this facility will help ensure the UK has a health

protection system fit for the future.”

**Stuart Grant, Chief Executive of Harwell Campus said:** “Starting construction of the Moderna Innovation and Technology Centre is an important milestone for the campus. It signifies the growing depth and breadth of innovative research into mRNA and nucleic acid therapeutics that is taking place at Harwell. We’re looking forward to working closely with Moderna to help them build connections and collaborations across our flourishing Health Tech cluster.”

**ENDS**

**Notes to editors:**

### **About Moderna**

In over 10 years since its inception, Moderna (known in the UK as Moderna Biotech UK) has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio and integrated manufacturing facilities that allow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. To learn more, visit [www.modernatx.co.uk](http://www.modernatx.co.uk)

### **Harwell Science and Innovation Campus**

Harwell is the UK's leading science and innovation campus, where government, academia and industry work together to solve the critical problems facing our planet. The campus is home to £3bn national facilities and 6,000 colleagues committed to scientific discovery and understanding.

Moderna is the latest organisation to join Harwell’s thriving Health Tech cluster which has grown to over 70 life science organisations since it launched in 2016.

The campus’ unique combination of expertise in the development of vaccines and mRNA technologies includes: Europe’s largest collection of open access, publicly funded scientific facilities, such as The Rosalind Franklin Institute and the Nucleic Acid Therapy Accelerator and commercial organisations including: Catalent, Vaccitech, NeoVac and Nanovation Therapeutics.

Harwell is managed and developed by a joint venture between the Science and Technology Facilities Council, the UK Atomic Energy Authority and the private sector investor, Brookfield.

Follow us on twitter and LinkedIn @HarwellCampus, or learn more here [www.harwellcampus.com](http://www.harwellcampus.com)

### **Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: construction of the Moderna Innovation and Technology Centre and Moderna’s ten-year strategic partnership with the UK government; Moderna’s aim for the facility to provide the UK public with access to domestically

manufactured mRNA respiratory vaccines, pending assessment and licensure; the anticipated creation of jobs during construction and operation of the facility; and expected timing for the Drug Substance and Manufacturing facility to become operational. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include those other risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at [www.sec.gov](http://www.sec.gov). Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.

### **Moderna contacts**

#### **Media:**

Emma Gilgunn-Jones  
UK Director of Communications  
[emma.gilgunn-jones@modernatx.com](mailto:emma.gilgunn-jones@modernatx.com)

#### **Investors:**

Lavina Talukdar  
Senior Vice President & Head of Investor Relations  
617-209-5834  
[Lavina.Talukdar@modernatx.com](mailto:Lavina.Talukdar@modernatx.com)

#### **Harwell contact**

Dan Metcalfe  
Director of Communications  
[dan.metcalfe@harwellcampus.com](mailto:dan.metcalfe@harwellcampus.com)

SOURCE: Moderna, Inc.